Department of Palliative Medicine, Poznan University of Medical Sciences, Poznan, Poland.
Palliat Med. 2013 May;27(5):470-7. doi: 10.1177/0269216312458823. Epub 2012 Sep 17.
Limited data exist on the validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 15 - Palliative Care in advanced cancer patients.
To adapt the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 15 - Palliative Care to the Polish clinical setting and to evaluate its psychometric properties in advanced cancer patients.
Two quality-of-life measurements were performed at baseline and after 7 days. The concurrent validity of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 15 - Palliative Care was established by the Pearson correlation coefficients with the modified Edmonton Symptom Assessment System, the Karnofsky Performance Status and the Brief Pain Inventory - Short Form. Reliability was assessed using Cronbach's alpha coefficients and the Spearman correlation coefficients of the baseline and of the second measurement of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 15 - Palliative Care items.
SETTING/PARTICIPANTS: A total of 160 consecutive patients in one academic palliative medicine centre were included.
A total of 129 patients completed the study. The concurrent validity revealed significant correlations of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 15 - Palliative Care pain scale with the Brief Pain Inventory - Short Form, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 15 - Palliative Care symptom items with the modified Edmonton Symptom Assessment System and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 15 - Palliative Care functional scales with the Karnofsky Performance Status scores. High Cronbach's alpha and standardised Cronbach's alpha values were found in the case of both functional (range: 0.830-0.925; 0.830-0.932) and symptom scales (range: 0.784-0.940; 0.794-0.941) of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 15 - Palliative Care, respectively. The Spearman correlation coefficients between the first and the second measurements were significant (p < 0.0001) for all European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 15 - Palliative Care items.
Polish version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 15 - Palliative Care is a valid and reliable tool recommended for quality-of-life assessment and monitoring in advanced cancer patients.
关于欧洲癌症研究与治疗组织（EORTC）生活质量问卷核心 15 项-晚期癌症患者的姑息治疗的验证数据有限。
将欧洲癌症研究与治疗组织（EORTC）生活质量问卷核心 15 项-姑息治疗改编为波兰临床环境，并评估其在晚期癌症患者中的心理测量特性。
在基线和 7 天后进行了两次生活质量测量。欧洲癌症研究与治疗组织（EORTC）生活质量问卷核心 15 项-姑息治疗的同时效度通过与改良的埃德蒙顿症状评估系统、卡诺夫斯基表现状态和简明疼痛量表-短表的 Pearson 相关系数来确定。使用 Cronbach's alpha 系数和欧洲癌症研究与治疗组织（EORTC）生活质量问卷核心 15 项-姑息治疗项目的基线和第二次测量的 Spearman 相关系数来评估可靠性。
地点/参与者：在一个学术姑息医学中心共纳入 160 例连续患者。
共有 129 例患者完成了研究。同时效度显示，欧洲癌症研究与治疗组织（EORTC）生活质量问卷核心 15 项-姑息治疗的疼痛量表与简明疼痛量表-短表显著相关，欧洲癌症研究与治疗组织（EORTC）生活质量问卷核心 15 项-姑息治疗的症状项目与改良的埃德蒙顿症状评估系统和欧洲癌症研究与治疗组织（EORTC）生活质量问卷核心 15 项-姑息治疗的功能量表与卡诺夫斯基表现状态评分显著相关。欧洲癌症研究与治疗组织（EORTC）生活质量问卷核心 15 项-姑息治疗的功能量表（范围：0.830-0.925；0.830-0.932）和症状量表（范围：0.784-0.940；0.794-0.941）均具有较高的 Cronbach's alpha 和标准化 Cronbach's alpha 值。欧洲癌症研究与治疗组织（EORTC）生活质量问卷核心 15 项-姑息治疗的所有项目的第一次和第二次测量之间的 Spearman 相关系数均有显著意义（p < 0.0001）。
波兰版的欧洲癌症研究与治疗组织（EORTC）生活质量问卷核心 15 项-姑息治疗是一种有效的、可靠的工具，推荐用于晚期癌症患者的生活质量评估和监测。
